Citations

Clear

499 citation(s) found for "Tracy, PB".

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1051-1069

10.1002/acr.25348 | PMID 38973731 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1070-1082

10.1002/acr.25347 | PMID 38973729 Get It

ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation.ResultsFifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs.ConclusionThis clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.
2023 American College of Rheumatology ( ACR )/American College of Chest Physicians ( CHEST ) Guideline for the Screening and Monitoring of Interstitial Lu
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis & Rheumatology | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1201-1213

10.1002/art.42860 | PMID 38973714 Get It

Objective We provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease. Methods We developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation. Results Fifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.
Stabilization of β-Catenin Directs HEB to Limit Thymic Selection
Tousinas, Georgios , Emmanuel, Akinola Olumide , Tracy, Melissa, Arnovitz, Stephen , Papamarcaki, Thomais, Gounari, Fotini , Olumide Emmanuel, Akinola , Papamarcaki, Thomais , Gounari, Fotini , Friedman, David

Mayo Clinic

The Journal of Immunology | July 3, 2024 | Volume: 213 | Issue: 5 | Pages: 641-650

10.4049/jimmunol.2400160 | PMID 38958395 Get It

Abstract Activation of β-catenin in CD4+CD8+ double-positive (DP) thymocytes halts development before the thymic selection stage and predisposes to transformation. Leukemogenesis, but not the developmental block, depends on TCF-1, β-catenin’s DNA-binding partner. In this study, we show that β-catenin activation directs the DNA-binding protein HEB to block DP thymocyte development. Conditional loss of HEB in DP thymocytes with stabilized β-catenin restores the frequencies of postselection TCRβhi/CCR7+ and TCRβhi/CD69+ DPs and their cell-cycle profile. This recovery is associated with significant reversal of β-catenin-induced expression changes, particularly those related to the CD69+ DP cell signature and to cell-cycle pathways. Stabilizing β-catenin in DP thymocytes directs HEB binding to ≈11,000 novel DNA sites throughout the genome. Novel HEB sites mark most CD69+ DP cell signature genes that change expression upon activation of β-catenin and then revert after loss of HEB. Moreover, many of the novel HEB sites occupy promoter regions of genes enriched in mitotic cell cycle pathways. HEB binding to those regions correlates with downregulation of the associated genes, and HEB inactivation restores expression to physiologic levels. These findings highlight a molecular interplay between HEB and β-catenin that can impair thymic development.
Epidemiologic Features of Recovery From SARS-CoV-2 Infection
Oelsner, Elizabeth C. , Sun, Yifei , Andrews, Howard , Carson, April P. , Cushman, Mary , Demmer, Ryan T. , Elkind, Mitchell S.V. , Gallo, Linda C. , Kandula, Namratha R. , Kaplan, Robert C. , Kucharska-Newton, Anna M., Lee, Joyce , Norwood, Arnita F. , Ortega, Victor E. , Gabriel, Kelley Pettee , Sotres‐Alvarez, Daniela , Shikany, James M., Thyagarajan, Bharat , Umans, Jason G. , Wenzel, Sally E. , Woodruff, Prescott G. , Zhang, Ying , Kucharska‐Newton, Anna , Carson, April P , Thyagarajan, Bharat , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T , Lee, Joyce S , Wenzel, Sally E , Balte, Pallavi , Allen, Norrina B. , Cole, Shelley A. , Coresh, Josef , Couper, David , Daviglus, Martha , Gutierrez, Jose D., Howard, Virginia J. , Isasi, Carmen R. , Judd, Suzanne E. , Kanaya, Alka M , Kinney, Gregory L. , Lackland, Daniel T. , Make, Barry J. , Min, Yuan‐I , Murabito, Joanne M. , Psaty, Bruce M. , Regan, Elizabeth Anne , Schwartz, David A. , Tracy, Russell P. , Vasan, Ramachandran S. , Xanthakis, Vanessa , Post, Wendy S. , Wenzel, Sally E.

Mayo Clinic

JAMA Network Open | June 17, 2024 | Volume: 7 | Issue: 6 | Pages: e2417440

10.1001/jamanetworkopen.2024.17440 | PMID 38884994 Get It

ImportancePersistent symptoms and disability following SARS-CoV-2 infection, known as post–COVID-19 condition or “long COVID,” are frequently reported and pose a substantial personal and societal burden.ObjectiveTo determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days.Design, Setting, and ParticipantsFor this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health–funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection.ExposurePreinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires.Main Outcomes and MeasuresProbability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days.ResultsOf 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P < .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections.Conclusions and RelevanceIn this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Abdelmessieh, Peter, Ali, Haris , Dunbar, Andrew , Revell, Rebecca, Green, Steven D. , Gundabolu, Krishna , Jamieson, Catriona, Kaesberg, Paul, Madanat, Yazan F. , Manchanda, Naveen, McMahon, Brandon , Nadiminti, Kalyan , Palmer, Jeanne , Patel, Anand , Rein, Lindsay , Salit, Rachel B. , Wadleigh, Martha , Wall, Sarah , Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Madanat, Yazan , Gotlib, Jason , Gerds, Aaron T. , Castells, Mariana , George, Tracy I. , Hexner, Elizabeth O. , Jain, Tania , Kuykendall, Andrew , Masárová, Lucia , May, Jori E. , Mohan, Sanjay , Oh, Stephen T. , Patel, Ami B. , Podoltsev, Nikolai , Talpaz, Moshe

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2024 | Volume: 22 | Issue: 2D | Pages: No page available

10.6004/jnccn.2024.0030 | PMID 38862005 Get It

Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended. The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.
Reply to Rollin et al.
Marôco, João Luís , Szymanski, Linda M. , Baynard, Tracy , Fernhall, Bo , Marôco, João , Marôco, João L , Marôco, João

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | May 31, 2024 | Volume: 326 | Issue: 6 | Pages: H1552-H1552

10.1152/ajpheart.00306.2024 | PMID 38820418 Get It

Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Li, Peng , Fnu, Alnoor, Xie, Wei , Williams, Margaret S., Feusier, Julie Feusier, Zhao, Xiangrong, Zheng, Gang , Zieski, Arthur, Tantravahi, Srinivas K. , Tashi, Tsewang , Patel, Jay , Miles, Rodney R., Jacobsen, Jeffrey, Sborov, Douglas W. , Szankasi, Philippe , Rindler, Paul M., Close, Devin , Ohgami, Robert S. , Li, Peng , Alnoor, Fnu , Williams, Margaret C. , Feusier, Julie , Ding, Yi , Zhao, Chen , Zieske, Arthur W., Zu, Youli , Raess, Philipp W. , Osman, Afaf E.G. , Patel, Ami B. , Matynia, Anna P., Menon, Madhu P , Jacobsen, Jeffrey, George, Tracy I.

Mayo Clinic

No container title available | May 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4397067/v1 Get It

Abstract VEXAS (vacuoles, E1-ubiquitin-like modifier activating enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory disorder caused by acquired UBA1 mutations in hematopoietic precursor cells. The prevalence, clinical significance, and genomic landscape of UBA1variants in patients with hematologic malignancies (HM) remains unexplored. We analyzed the genomic profiles of 86 patients carrying 17 different UBA1variants amongst an unbiased cohort of 8,976 HM patients. Specific genetic and clinical features seen more frequently in patients with UBA1 pathogenic variants (PV) versus those with variants of uncertain significance (VUS) included: marked male predominance (98% versus 80%, P=0.002), macrocytic anemia (MCV 105 ± 1.4 fl versus 96 ± 1.4 fl, p=0.01), frequent dominant clones without concurrent somatic variants (53% versus 15%, p=0.004), and association with molecularly distinct low-risk myelodysplastic syndrome (MDS; 13%) with superior overall survival (OS). Interestingly, while the genetic profiles of UBA1 PV patients resemble patients with clonal cytopenia of unknown significance (CCUS), rapid UBA1 clonal expansion predispose patients to convert to low-grade MDS with a notably hastened progression compared to UBA1 wild-type CCUS. This “clone surge to clinical stability” (CS) is a mechanism that emphasizes the unique pathobiology of UBA1mutations in VEXAS and supports it as a distinct entity.
Tolvaptan Modifies Patient Risk Class Distribution Over Time in Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Data From the TEMPO 3:4 Trial
Japes, Hina, Tracy, LaRee , Mccormick, Linda, Maringer, Katherine, Nourbakhsh, Ali, Dahl, Neera K. , Chebib, Fouad T. , Rahbari-Oskoui, Frederic F. , Jiang, Huan , Perrone, Ronald D. , Nourbakhsh, Ali

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 161-162

10.1681/asn.20223311s1161d Get It

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis
Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Frishberg, Yaacov, Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Habtemarian, Bahru A., Bhan, Ishir , McGregor, Tracy L., Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B2-B2

10.1681/asn.20213210s1b2a Get It